Top Proteomic Biomarkers Market Companies: A Deep Dive into Key Players

By /

Proteomic Biomarkers Market Companies

Proteomic Biomarkers Market Companies
  • Thermo Fisher Scientific Inc.
  • Agilent Technologies Inc.
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Waters Corporation
  • Bruker Corporation
  • PerkinElmer, Inc.
  • Merck KGaA
  • Shimadzu Corporation
  • Roche Diagnostics
  • Qiagen N.V.
  • Luminex Corporation
  • Illumina, Inc.
  • Caprion Proteomics Inc.
  • Meso Scale Diagnostics, LLC.

Get Sample Report

1. Thermo Fisher Scientific Inc.

  • Company Name and Headquarters: Thermo Fisher Scientific Inc., Waltham, Massachusetts, USA

  • Product Offerings Related to Proteomic Biomarkers: Thermo Fisher is a powerhouse in proteomics. Their offerings include:

    • Mass Spectrometry Platforms: Orbitrap (Q Exactive, Fusion Lumos, Exploris series), TSQ series for targeted proteomics, and MALDI-TOF systems.

    • Chromatography Systems: HPLC, UHPLC, and nano-LC systems crucial for sample separation before MS analysis.

    • Sample Preparation Kits & Reagents: Kits for protein extraction, digestion, and fractionation.

    • Bioinformatics Software: Proteome Discoverer, Compound Discoverer, and various other software solutions for data analysis and interpretation.

    • Antibodies & Immunoassays: A vast catalog of antibodies and ELISA kits applicable for biomarker validation.

  • Market Share and Estimated Revenue from Proteomic Biomarkers Segment: Thermo Fisher holds a significant leadership position in the broader proteomics tools market, especially in mass spectrometry. While specific revenue figures for “proteomic biomarkers segment” are not publicly disaggregated, their life science solutions, which include proteomics tools, contribute billions in revenue annually, with a substantial portion driven by biomarker research applications. Their market share in proteomics instrumentation is estimated to be among the highest, particularly in high-end MS.

  • Recent Developments, Partnerships, or Innovations:

    • Continuous advancements in Orbitrap technology for higher sensitivity, speed, and resolution.

    • Development of TMTpro 16-plex and 18-plex reagents for multiplexed protein quantification.

    • Increased focus on clinical proteomics applications and translational research.

    • Acquisitions to strengthen specific areas, e.g., Patheon for contract development and manufacturing, indirectly supporting biomarker development.

  • Competitive Positioning and Strategic Focus: A dominant player known for its comprehensive portfolio, technological innovation (especially in MS), and strong global presence. Strategic focus on integrated workflows, high-throughput solutions, and expanding into clinical diagnostics and precision medicine.

  • Key Customers or Industries Served: Academic research institutions, pharmaceutical and biotechnology companies, contract research organizations (CROs), clinical research labs, government agencies.

2. Agilent Technologies Inc.

  • Company Name and Headquarters: Agilent Technologies Inc., Santa Clara, California, USA

  • Product Offerings Related to Proteomic Biomarkers: Agilent provides a robust suite of tools for proteomics:

    • Mass Spectrometry: Q-TOF (e.g., Agilent 6500 series), Triple Quadrupole (e.g., 6400 series) for targeted assays, and ICP-MS for metalloproteins.

    • Liquid Chromatography Systems: HPLC and UHPLC systems (e.g., Agilent 1290 Infinity II) optimized for proteomics.

    • Electrophoresis Systems: Capillary electrophoresis (CE) for protein separation.

    • Microarrays: Protein microarrays for high-throughput biomarker screening.

    • Bioinformatics Software: MassHunter software suite for MS data analysis.

  • Market Share and Estimated Revenue from Proteomic Biomarkers Segment: Agilent is a strong contender in the analytical instrumentation market, including proteomics. While specific biomarker revenue is not isolated, their life science and applied markets group generates billions, with proteomics-related tools contributing significantly. They hold a strong market share in LC-MS systems.

  • Recent Developments, Partnerships, or Innovations:

    • Enhanced Q-TOF platforms for improved sensitivity and dynamic range in proteomic analysis.

    • Development of integrated workflows for clinical research and biomarker discovery.

    • Focus on automation and user-friendliness for routine proteomic applications.

  • Competitive Positioning and Strategic Focus: A leading provider of integrated analytical solutions, known for reliable instrumentation and strong support. Strategic focus on delivering end-to-end workflows, expanding into clinical research, and digital lab solutions.

  • Key Customers or Industries Served: Pharmaceutical and biotechnology companies, academic research institutions, government and environmental labs, clinical diagnostic labs.

3. Bio-Rad Laboratories, Inc.

  • Company Name and Headquarters: Bio-Rad Laboratories, Inc., Hercules, California, USA

  • Product Offerings Related to Proteomic Biomarkers: Bio-Rad has a strong legacy in protein separation and analysis:

    • Electrophoresis Systems: SDS-PAGE, 2D-PAGE, and blotting systems (e.g., Criterion, Mini-PROTEAN) essential for protein analysis and biomarker visualization.

    • Imaging Systems: Western blot imaging systems (e.g., ChemiDoc, Gel Doc).

    • Immunoassay Platforms: ELISA kits, multiplex immunoassay systems (e.g., Bio-Plex MagPix/Luminex-based) for high-throughput quantification of multiple biomarkers.

    • Protein Purification & Sample Prep: Chromatography resins, columns, and kits for protein isolation.

    • Antibodies & Reagents: A broad portfolio of primary and secondary antibodies.

  • Market Share and Estimated Revenue from Proteomic Biomarkers Segment: Bio-Rad is a significant player in the protein analysis and immunoassay markets. While specific revenue for “proteomic biomarkers” isn’t disclosed, their Life Science segment, which houses these products, generates hundreds of millions to over a billion annually, with biomarker research being a key application area. They have a strong presence in traditional protein analysis techniques and multiplex immunoassays.

  • Recent Developments, Partnerships, or Innovations:

    • Introduction of enhanced imaging systems and reagents.

    • Expansion of their multiplex immunoassay panels.

    • Focus on automating protein analysis workflows.

  • Competitive Positioning and Strategic Focus: Strong in traditional protein biochemistry tools and multiplex immunoassays. Strategic focus on providing complete solutions for protein separation, detection, and quantification, with an increasing emphasis on clinical research applications.

  • Key Customers or Industries Served: Academic research labs, pharmaceutical and biotechnology companies, clinical diagnostic labs, government research institutions.

4. Danaher Corporation

  • Company Name and Headquarters: Danaher Corporation, Washington D.C., USA

  • Product Offerings Related to Proteomic Biomarkers: Danaher is a diversified science and technology innovator. Its relevant subsidiaries for proteomic biomarkers include:

    • SCIEX (Mass Spectrometry): Q-TOF (e.g., ZenoTOF 7600), Triple Quadrupole (e.g., QTRAP, TripleTOF) systems for discovery and targeted proteomics.

    • Pall Corporation (Separation & Filtration): Products for sample preparation, protein purification, and filtration.

    • Cytiva (Bioprocess & Life Science Research): Protein purification systems (e.g., ÄKTA series), chromatography media, and reagents.

    • Leica Microsystems (Microscopy): Imaging systems for cell and tissue analysis, relevant for protein localization.

  • Market Share and Estimated Revenue from Proteomic Biomarkers Segment: Danaher, through its operating companies like SCIEX and Cytiva, holds a significant share in the mass spectrometry and bioprocess markets, which are integral to proteomic biomarker research. Their Life Sciences segment revenue is in the billions, with a substantial portion attributable to tools used in biomarker discovery and development. SCIEX is a top-tier provider of mass spectrometry solutions.

  • Recent Developments, Partnerships, or Innovations:

    • SCIEX’s continuous innovation in mass spectrometry, including enhanced sensitivity and speed for deep proteome profiling and targeted assays.

    • Cytiva’s advancements in protein purification and bioprocessing workflows.

    • Integration of capabilities across its operating companies for more complete workflows.

  • Competitive Positioning and Strategic Focus: A powerful conglomerate with strong brands in critical segments of the proteomics workflow. Strategic focus on innovation within its operating companies, providing integrated solutions, and expanding its presence in biopharma and clinical research.

  • Key Customers or Industries Served: Pharmaceutical and biotechnology companies, academic research institutions, contract research organizations (CROs), clinical diagnostic labs, biomanufacturing.

5. Waters Corporation

  • Company Name and Headquarters: Waters Corporation, Milford, Massachusetts, USA

  • Product Offerings Related to Proteomic Biomarkers: Waters is renowned for its chromatography and mass spectrometry expertise:

    • Mass Spectrometry: Q-TOF (e.g., SYNAPT, Xevo G2-XS), Triple Quadrupole (e.g., Xevo TQ), and ion mobility MS (IMS) for advanced proteomic characterization.

    • Liquid Chromatography Systems: UPLC and HPLC systems (e.g., ACQUITY UPLC) designed for high-resolution protein and peptide separation.

    • Sample Preparation: Consumables and reagents for sample clean-up.

    • Bioinformatics Software: UNIFI, MassLynx, and BiopharmaLynx for comprehensive data processing and interpretation.

  • Market Share and Estimated Revenue from Proteomic Biomarkers Segment: Waters is a leading provider of high-performance liquid chromatography and mass spectrometry systems. While specific revenue for “proteomic biomarkers” is not broken out, their analytical technologies are fundamental to biomarker research, contributing significantly to their multi-billion dollar annual revenue. They hold a strong market share in UPLC and high-end MS for biopharmaceutical applications.

  • Recent Developments, Partnerships, or Innovations:

    • Introduction of next-generation mass spectrometry platforms with enhanced sensitivity and resolution.

    • Development of integrated workflows for biopharmaceutical characterization and clinical research proteomics.

    • Focus on simplified and robust methods for biomarker quantification.

  • Competitive Positioning and Strategic Focus: A premium brand known for cutting-edge chromatography and mass spectrometry technologies, particularly strong in biopharmaceutical analysis. Strategic focus on innovation, providing high-value solutions for complex analytical challenges, and expanding into clinical and translational research.

  • Key Customers or Industries Served: Pharmaceutical and biotechnology companies, academic research institutions, CROs, government agencies, food and environmental testing.

6. Bruker Corporation

  • Company Name and Headquarters: Bruker Corporation, Billerica, Massachusetts, USA

  • Product Offerings Related to Proteomic Biomarkers: Bruker is a key player in high-performance scientific instruments:

    • Mass Spectrometry: MALDI-TOF (e.g., timsTOF fleX, MALDI Biotyper), timsTOF Pro (PASEF technology for deep and fast proteomics), and FT-ICR MS.

    • NMR Spectroscopy: For structural biology and metabolomics, which complements proteomics.

    • Protein Crystallography: Instruments for structural determination.

    • Proteomics Software: Compass for HRAM MS, SCiLS Lab, and various others for data analysis.

  • Market Share and Estimated Revenue from Proteomic Biomarkers Segment: Bruker has a strong niche in specific mass spectrometry technologies, particularly MALDI-TOF and advanced ion mobility MS (timsTOF). Their CALID division (mass spectrometry) generates hundreds of millions in revenue, with a significant portion driven by proteomics applications. They are a leader in rapid pathogen identification via MALDI-TOF, which has biomarker parallels.

  • Recent Developments, Partnerships, or Innovations:

    • Breakthroughs with timsTOF Pro and PASEF technology, enabling ultra-fast, deep, and sensitive proteome profiling.

    • Increased focus on clinical proteomics and single-cell proteomics applications.

    • Partnerships to develop advanced proteomic workflows.

  • Competitive Positioning and Strategic Focus: Known for highly innovative and specialized mass spectrometry technologies, particularly for deep and fast proteomics. Strategic focus on pushing the boundaries of analytical performance, expanding into clinical research, and single-cell analysis.

  • Key Customers or Industries Served: Academic research institutions, pharmaceutical and biotechnology companies, clinical microbiology labs, government research.

7. PerkinElmer, Inc.

  • Company Name and Headquarters: PerkinElmer, Inc., Waltham, Massachusetts, USA

  • Product Offerings Related to Proteomic Biomarkers: PerkinElmer offers a broad range of life science tools and diagnostics:

    • Immunoassay Platforms: Automated immunoassay systems (e.g., JANUS, VICTOR, EnSpire) for high-throughput screening of protein biomarkers.

    • Reagents & Consumables: A wide array of detection reagents, antibodies, and immunoassay kits.

    • Imaging Systems: High-content screening systems for cellular analysis relevant to protein expression and localization.

    • Liquid Handling & Automation: Automated liquid handlers for sample preparation in biomarker assays.

  • Market Share and Estimated Revenue from Proteomic Biomarkers Segment: PerkinElmer holds a strong position in high-throughput screening, immunoassay, and diagnostics. While a specific proteomic biomarker revenue isn’t detailed, their Discovery & Analytical Solutions segment, which includes these tools, generates billions, with biomarker research and diagnostic development as key drivers.

  • Recent Developments, Partnerships, or Innovations:

    • Enhanced automation and high-throughput capabilities for biomarker screening.

    • Development of new immunoassay panels and detection technologies.

    • Strategic acquisitions to strengthen diagnostic capabilities.

  • Competitive Positioning and Strategic Focus: A strong player in high-throughput screening, automation, and diagnostic assay development. Strategic focus on integrated solutions for life science research and diagnostics, with an emphasis on precision health.

  • Key Customers or Industries Served: Pharmaceutical and biotechnology companies, academic research institutions, clinical diagnostic labs, government labs, CROs.

8. Merck KGaA

  • Company Name and Headquarters: Merck KGaA (also known as EMD Millipore in North America), Darmstadt, Germany

  • Product Offerings Related to Proteomic Biomarkers: Merck provides a vast range of products for life science research and bioprocessing:

    • Antibodies & Immunoassays: A comprehensive portfolio of primary and secondary antibodies, ELISA kits, and multiplex immunoassay kits (e.g., MILLIPLEX Luminex-based assays).

    • Protein Purification & Sample Prep: Chromatography media, filtration devices, protein extraction kits, and mass spectrometry sample prep reagents.

    • Cell Culture Media & Reagents: Essential for studies involving cellular protein expression.

    • Western Blotting: Reagents and membranes.

  • Market Share and Estimated Revenue from Proteomic Biomarkers Segment: Merck is a dominant supplier of reagents, consumables, and tools for life science research and bioprocessing. Their Life Science business generates billions, with a substantial portion supporting proteomic biomarker discovery, validation, and development. They are a key provider of multiplex immunoassay kits and general lab reagents.

  • Recent Developments, Partnerships, or Innovations:

    • Expansion of their MILLIPLEX multiplex assay panels for various disease areas.

    • Continuous development of advanced protein purification and separation technologies.

    • Focus on integrated workflows for biopharmaceutical research and development.

  • Competitive Positioning and Strategic Focus: A global leader in life science tools, reagents, and services. Strategic focus on providing high-quality research tools, advancing bioprocessing, and supporting drug discovery and development, including biomarker applications.

  • Key Customers or Industries Served: Academic research institutions, pharmaceutical and biotechnology companies, contract research organizations (CROs), diagnostics developers.

9. Shimadzu Corporation

  • Company Name and Headquarters: Shimadzu Corporation, Kyoto, Japan

  • Product Offerings Related to Proteomic Biomarkers: Shimadzu is a major analytical instrumentation company:

    • Mass Spectrometry: MALDI-TOF (e.g., AccuSpot, MALDI-8020), Triple Quadrupole (e.g., LCMS-8060, 8045) for targeted proteomics, and Q-TOF systems.

    • Liquid Chromatography Systems: HPLC and UHPLC systems (e.g., Nexera series) widely used for peptide and protein separation.

    • Spectrophotometry: UV-Vis and Fluorescence spectrophotometers.

    • Proteomics Software: LabSolutions and various specialized software for MS data analysis.

  • Market Share and Estimated Revenue from Proteomic Biomarkers Segment: Shimadzu holds a strong position in the analytical instrumentation market, particularly in LC and LC-MS. While specific proteomics biomarker revenue is not segmented, their analytical and measuring instruments division contributes significantly to their multi-billion dollar revenue, with proteomics being a key application area for their MS and LC products.

  • Recent Developments, Partnerships, or Innovations:

    • Introduction of highly sensitive and fast triple quadrupole mass spectrometers for clinical research proteomics.

    • Advancements in MALDI-TOF systems for rapid analysis.

    • Integration of AI and automation into analytical workflows.

  • Competitive Positioning and Strategic Focus: A strong global player known for reliable and high-performance analytical instrumentation. Strategic focus on expanding their mass spectrometry portfolio, developing integrated solutions, and targeting clinical research and precision medicine applications.

  • Key Customers or Industries Served: Academic research institutions, pharmaceutical and biotechnology companies, government agencies, food and environmental labs, clinical research labs.

10. Roche Diagnostics

  • Company Name and Headquarters: Roche Diagnostics (a division of F. Hoffmann-La Roche AG), Basel, Switzerland (headquarters of parent company)

  • Product Offerings Related to Proteomic Biomarkers: Roche Diagnostics is a global leader in in-vitro diagnostics and tissue-based diagnostic solutions:

    • Immunodiagnostics Platforms: Fully automated immunoassay analyzers (e.g., cobas systems) for the detection and quantification of clinically relevant protein biomarkers in patient samples.

    • Reagents & Assays: A vast menu of FDA-approved and CE-marked assays for various disease areas (e.g., oncology, cardiology, infectious diseases), many of which are protein-based biomarkers.

    • Tissue Diagnostics: Immunohistochemistry (IHC) and in situ hybridization (ISH) platforms and reagents (e.g., Ventana systems) for protein biomarker analysis in tissues.

    • Molecular Diagnostics: While primarily DNA/RNA-focused, these often complement proteomic biomarker studies.

  • Market Share and Estimated Revenue from Proteomic Biomarkers Segment: Roche Diagnostics is arguably the largest player in the in-vitro diagnostics market, with billions in annual revenue directly from diagnostic tests. Their market share in many clinical immunoassay segments is dominant. A very substantial portion of this revenue is directly attributable to proteomic biomarkers used in clinical settings.

  • Recent Developments, Partnerships, or Innovations:

    • Continuous development of new diagnostic assays for emerging protein biomarkers.

    • Focus on integrated digital pathology and diagnostic solutions.

    • Strategic collaborations to advance precision medicine through companion diagnostics.

  • Competitive Positioning and Strategic Focus: The undisputed leader in in-vitro diagnostics, with a vast installed base of instruments and a comprehensive menu of clinically validated assays. Strategic focus on expanding their diagnostics portfolio, driving precision medicine, and leveraging AI and digital solutions in diagnostics.

  • Key Customers or Industries Served: Hospitals, clinical diagnostic laboratories, reference laboratories, blood banks, pharmaceutical companies (for companion diagnostics).

11. Qiagen N.V.

  • Company Name and Headquarters: Qiagen N.V., Venlo, Netherlands

  • Product Offerings Related to Proteomic Biomarkers: Qiagen is a leading global provider of sample and assay technologies:

    • Sample Preparation: Kits and automated systems for protein extraction, purification, and fractionation from various biological samples, critical upstream of proteomic analysis.

    • Assay Technologies: ELISA kits, proteome profiler arrays, and related reagents for targeted protein biomarker detection.

    • Bioinformatics Software: Ingenuity Pathway Analysis (IPA) which integrates proteomic data with biological pathways and networks to identify biomarkers.

    • Automated Solutions: QIAcube, QIAxpert for automated sample processing.

  • Market Share and Estimated Revenue from Proteomic Biomarkers Segment: Qiagen is a strong player in sample preparation and bioinformatics. While specific proteomics biomarker revenue is not separated, their overall portfolio generates billions, with sample prep and bioinformatics being essential components for biomarker workflows. Their market share in sample preparation is substantial.

  • Recent Developments, Partnerships, or Innovations:

    • Development of advanced protein sample preparation solutions for challenging samples.

    • Enhancements in bioinformatics tools for proteomic data interpretation.

    • Focus on automation to improve throughput and reproducibility.

  • Competitive Positioning and Strategic Focus: A leader in sample preparation technologies and bioinformatics, enabling downstream proteomic analysis. Strategic focus on providing integrated sample-to-insight solutions, expanding into clinical research, and leveraging bioinformatics for deeper biological understanding.

  • Key Customers or Industries Served: Academic research institutions, pharmaceutical and biotechnology companies, clinical diagnostic labs, government labs.

12. Luminex Corporation

  • Company Name and Headquarters: Luminex Corporation, Austin, Texas, USA (now part of DiaSorin S.p.A.)

  • Product Offerings Related to Proteomic Biomarkers: Luminex is known for its xMAP multiplexing technology:

    • xMAP Technology: Bead-based multiplexing platform for simultaneously analyzing up to 500 different analytes (including proteins/biomarkers) from a single sample.

    • Instruments: xMAP MAGPIX, LUMINEZ 200, FLEXMAP 3D systems.

    • Reagents & Assays: Develops and licenses its technology for various protein biomarker panels (e.g., cytokine panels, immunoassay panels).

    • ARIES Systems: Molecular diagnostic platform (though their xMAP is more relevant for proteomic biomarkers).

  • Market Share and Estimated Revenue from Proteomic Biomarkers Segment: Luminex has a strong market presence in multiplex protein detection. While now part of DiaSorin, their xMAP technology has been widely adopted globally, generating significant revenue for itself and its partners through kits and instruments. They hold a leading share in bead-based multiplex immunoassays.

  • Recent Developments, Partnerships, or Innovations:

    • Continuous expansion of assay menu and partnerships for developing new biomarker panels.

    • Focus on improving automation and ease of use for multiplex assays.

    • Acquired by DiaSorin S.p.A. in 2021, strengthening DiaSorin’s position in multiplexing.

  • Competitive Positioning and Strategic Focus: A leader in bead-based multiplexing technology, enabling cost-effective, high-throughput analysis of multiple protein biomarkers. Strategic focus on expanding the utility of xMAP technology across research and clinical applications and leveraging synergies with DiaSorin.

  • Key Customers or Industries Served: Academic research institutions, pharmaceutical and biotechnology companies, clinical diagnostic labs, CROs, government labs.

13. Illumina, Inc.

  • Company Name and Headquarters: Illumina, Inc., San Diego, California, USA

  • Product Offerings Related to Proteomic Biomarkers: While primarily known for genomics, Illumina has expanded its reach into proteomics through strategic moves:

    • Olink Proteomics Partnership/Acquisition: Illumina partnered with (and later acquired parts of) Olink Proteomics, which uses Proximity Extension Assay (PEA) technology to leverage NGS platforms for high-throughput, multiplexed protein biomarker analysis.

    • Next-Generation Sequencing (NGS) Platforms: While core to genomics, these platforms are utilized by PEA for readout of hundreds to thousands of protein biomarkers simultaneously.

    • Related Bioinformatics: Tools for managing and interpreting large datasets, including proteomic data.

  • Market Share and Estimated Revenue from Proteomic Biomarkers Segment: Illumina dominates the genomics market. Their foray into proteomics via Olink positions them to capture a share of the high-throughput protein biomarker market, leveraging their massive installed base of NGS instruments. While it’s a newer segment for them, the potential revenue from proteomic applications of NGS is significant.

  • Recent Developments, Partnerships, or Innovations:

    • Full acquisition of specific Olink assets (e.g., Explore product line) to integrate protein biomarker analysis directly onto NGS platforms.

    • Development of ultra-high-throughput protein analysis panels.

    • Efforts to bridge genomics and proteomics data for multi-omics insights.

  • Competitive Positioning and Strategic Focus: A genomics giant expanding into proteomic analysis by leveraging its established NGS infrastructure. Strategic focus on becoming a leader in multi-omics, offering integrated genomic and proteomic solutions for precision medicine, and driving high-throughput protein biomarker discovery.

  • Key Customers or Industries Served: Academic research institutions, pharmaceutical and biotechnology companies, clinical research labs, population genomics initiatives.

14. Caprion Proteomics Inc.

  • Company Name and Headquarters: Caprion Proteomics Inc., Montreal, Canada (now part of CellCarta)

  • Product Offerings Related to Proteomic Biomarkers: Caprion was a leading CRO specializing in proteomics and immune monitoring, now operating as a core part of CellCarta:

    • Quantitative Proteomics Services: Offering various mass spectrometry-based services for biomarker discovery, validation, and targeted quantification (e.g., label-free, TMT, SWATH-MS).

    • Immune Monitoring Services: Flow cytometry, ELISpot, and other assays for immune profiling and immunogenicity assessment, often linked to protein biomarkers.

    • Biomarker Discovery & Validation: Expertise in identifying and validating protein biomarkers for drug development and clinical trials.

    • Bioinformatics & Data Analysis: Comprehensive data interpretation.

  • Market Share and Estimated Revenue from Proteomic Biomarkers Segment: As a CRO, Caprion (now CellCarta) holds a significant share in the specialized contract research market for proteomics. Revenue is generated through service contracts with biopharma. They are a recognized leader in deep, quantitative proteomic analysis services.

  • Recent Developments, Partnerships, or Innovations:

    • Continuous investment in advanced mass spectrometry platforms and workflows.

    • Integration of multi-omics approaches (proteomics + genomics/immunology).

    • Acquisition by CellCarta (in 2020) to form a larger, more comprehensive CRO in immune monitoring and proteomics.

  • Competitive Positioning and Strategic Focus: A leading specialized CRO providing high-quality, in-depth proteomic and immune monitoring services. Strategic focus on supporting biopharmaceutical R&D, clinical trials, and personalized medicine initiatives by providing critical biomarker insights.

  • Key Customers or Industries Served: Pharmaceutical and biotechnology companies, academic research collaborators, clinical trial sponsors.

15. Meso Scale Diagnostics, LLC. (MSD)

  • Company Name and Headquarters: Meso Scale Diagnostics, LLC., Rockville, Maryland, USA

  • Product Offerings Related to Proteomic Biomarkers: MSD is a pioneer in multiplex electrochemiluminescence (ECL) immunoassays:

    • MULTI-ARRAY Technology: High-sensitivity, multiplexed immunoassay platform using ECL detection for measuring multiple protein biomarkers from a single small sample.

    • Instruments: MESO QuickPlex SQ 120, MESO V-PLEX instruments.

    • Assay Kits & Reagents: A broad portfolio of validated biomarker assay kits for various research areas (e.g., oncology, neurology, inflammation, immunology).

    • Custom Assay Development: Services for developing proprietary biomarker assays.

  • Market Share and Estimated Revenue from Proteomic Biomarkers Segment: MSD holds a strong and recognized position in the high-sensitivity, multiplex immunoassay market. While privately held, their technology is widely used in pharma and academic research, generating substantial revenue from instrument sales and assay kits. They are considered a leader in ECL-based multiplexing.

  • Recent Developments, Partnerships, or Innovations:

    • Continuous expansion of their V-PLEX and U-PLEX assay panels, offering highly validated and customizable protein biomarker quantification.

    • Focus on increasing throughput and automation for clinical research applications.

    • Partnerships with pharmaceutical companies for companion diagnostic development.

  • Competitive Positioning and Strategic Focus: A leader in high-sensitivity, multiplex electrochemiluminescence immunoassays, valued for its robust technology and extensive assay menu. Strategic focus on providing best-in-class tools for protein biomarker quantification, supporting drug discovery and development, and expanding into clinical utility.

  • Key Customers or Industries Served: Pharmaceutical and biotechnology companies, academic research institutions, contract research organizations (CROs), clinical research labs.

Contact Us

Related Posts

Scroll to Top